ARS Pharmaceuticals, Inc (SPRY) earnings · rev $84.3M
These earnings events as JSON? API free 100/dayARS Pharmaceuticals, Inc (SPRY) is a biotechnology company listed on NASDAQ.
This SPRY earnings page is the cached print — revenue, income, and the latest exhibit — not a live call transcript.
Latest reported SPRY revenue for 2025-12-31 was $84.3M. Net income was -$171.3M. Revenue was down 5.5% from 2024-12-31 to 2025-12-31. SPRY currently screens at market cap $983.1M.
When the next SPRY 8-K Item 2.02 lands, this page should move. Until then the SEC archive is the source.
The change that matters: Revenue was down 5.5% from 2024-12-31 to 2025-12-31. An earnings headline that ignores that move is noise.
Not investment advice. Full SPRY research stays on the stock page; the tape stays on the quote page.
SPRY earnings FAQ
What are SPRY's latest revenue and net income?
Latest cached ARS Pharmaceuticals, Inc (SPRY) revenue for Dec 31, 2025 was $84.3M. Net income was -$171.3M. Statements: https://lician.com/financials/spry
What is SPRY's latest diluted EPS?
Latest cached ARS Pharmaceuticals, Inc (SPRY) diluted EPS for Dec 31, 2025 was -$1.74.
What period does the latest SPRY earnings print cover?
The latest cached ARS Pharmaceuticals, Inc (SPRY) earnings print covers Dec 31, 2025. The prior cached period on this page is Dec 31, 2024.
How did SPRY revenue change from the prior cached period?
Cached ARS Pharmaceuticals, Inc (SPRY) revenue was down 5.5% from $89.1M (Dec 31, 2024) to $84.3M (Dec 31, 2025). Statements: https://lician.com/financials/spry
Where are SPRY earnings listed?
Cached earnings facts for ARS Pharmaceuticals, Inc (SPRY) are listed at https://lician.com/earnings/spry. Statements: https://lician.com/financials/spry
Not investment advice.